

# Genitourinary syndrome of menopause

Menopause

21, 1063-1068

DOI: [10.1097/gme.0000000000000329](https://doi.org/10.1097/gme.0000000000000329)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Vaginal Estrogen for Genitourinary Syndrome of Menopause. <i>Obstetrics and Gynecology</i> , 2014, 124, 1147-1156.	1.2	229
2	Management of Menopausal Symptoms. <i>Obstetrics and Gynecology</i> , 2015, 126, 859-876.	1.2	138
3	Vulvar and Vaginal Atrophy. <i>Clinical Obstetrics and Gynecology</i> , 2015, 58, 476-491.	0.6	94
4	The "Genitourinary Syndrome of Menopause". <i>Journal of Lower Genital Tract Disease</i> , 2015, 19, 362-363.	0.9	4
5	The Recent Review of the Genitourinary Syndrome of Menopause. <i>Journal of Menopausal Medicine</i> , 2015, 21, 65.	0.3	114
6	How old is too old for hormone therapy?. <i>Menopause</i> , 2015, 22, 258-259.	0.8	1
7	Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2703-2714.	0.9	17
8	Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. <i>Journal of Sexual Medicine</i> , 2015, 12, 2401-2412.	0.3	70
9	Menopausal Hormone Therapy. <i>Endocrinology and Metabolism Clinics of North America</i> , 2015, 44, 565-585.	1.2	12
10	Menopause. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15004.	18.1	288
11	Menopause. <i>Medical Clinics of North America</i> , 2015, 99, 521-534.	1.1	232
12	An update on drugs for the treatment of menopausal symptoms. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2437-2447.	0.9	13
13	Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3975-4011.	1.8	589
14	Refinement and expansion of a tool for measuring genitourinary syndrome of menopause. <i>Menopause</i> , 2016, 23, 355-356.	0.8	1
15	Patient considerations in the management of menopausal symptoms: role of conjugated estrogens with bazedoxifene. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 549.	0.9	7
16	2015 ISSVD, ISSWSH, and IPPS Consensus Terminology and Classification of Persistent Vulvar Pain and Vulvodynia. <i>Journal of Lower Genital Tract Disease</i> , 2016, 20, 126-130.	0.9	176
17	Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. <i>Menopause</i> , 2016, 23, 243-256.	0.8	181
18	Quantification of vaginal atrophy: several decades of advances. <i>Menopause</i> , 2016, 23, 823-824.	0.8	1

#	ARTICLE	IF	CITATIONS
19	An introduction to the Endocrine Society Clinical Practice Guideline on treatment of symptoms of the menopause. <i>Post Reproductive Health</i> , 2016, 22, 6-8.	0.3	7
20	Pharmacologic Therapies in Women's Health. <i>Medical Clinics of North America</i> , 2016, 100, 763-789.	1.1	6
21	2015 ISSVD, ISSWSH, and IPPS Consensus Terminology and Classification of Persistent Vulvar Pain and Vulvodynia. <i>Journal of Sexual Medicine</i> , 2016, 13, 607-612.	0.3	144
22	Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5 mg intravaginal prasterone for 12 weeks. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 159, 142-153.	1.2	64
23	Putative functions of tissue kallikrein-related peptidases in vaginal fluid. <i>Nature Reviews Urology</i> , 2016, 13, 596-607.	1.9	21
24	TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women with Vulvar and Vaginal Atrophy: The REJOICE Trial. <i>Journal of Sexual Medicine</i> , 2016, 13, 1930-1937.	0.3	12
25	Microablative fractional CO <sub>2</sub> -laser therapy and the genitourinary syndrome of menopause: An observational study. <i>Maturitas</i> , 2016, 94, 131-136.	1.0	91
26	Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 704-711.	0.7	274
27	Attitudes and perceptions towards vulvar and vaginal atrophy in Italian post-menopausal women: Evidence from the European REVIVE survey. <i>Maturitas</i> , 2016, 91, 74-80.	1.0	30
28	The REVIVE (REal Women's Views of Treatment Options for Menopausal Vaginal ChangEs) survey in Europe: Country-specific comparisons of postmenopausal women's perceptions, experiences and needs. <i>Maturitas</i> , 2016, 91, 81-90.	1.0	47
29	What's new in the world of postmenopausal sex?. <i>Current Opinion in Obstetrics and Gynecology</i> , 2016, 28, 449-454.	0.9	6
30	Ospemifene's effect on vasomotor symptoms: a post hoc analysis of phase 2 and 3 clinical data. <i>Menopause</i> , 2016, 23, 957-964.	0.8	13
31	Vulvovaginal symptoms prevalence in postmenopausal women and relationship to other menopausal symptoms and pelvic floor disorders. <i>Menopause</i> , 2016, 23, 368-375.	0.8	44
32	Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group. <i>Gynecological Endocrinology</i> , 2016, 32, 602-606.	0.7	30
33	2015 ISSVD, ISSWSH and IPPS Consensus Terminology and Classification of Persistent Vulvar Pain and Vulvodynia. <i>Obstetrics and Gynecology</i> , 2016, 127, 745-751.	1.2	189
34	Effect of <i>Foeniculum vulgare</i> (fennel) vaginal cream on vaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled trial. <i>Maturitas</i> , 2016, 84, 75-80.	1.0	48
35	The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms. <i>Postgraduate Medicine</i> , 2017, 129, 340-351.	0.9	19
36	The Women's EMPOWER Survey: Women's Knowledge and Awareness of Treatment Options for Vulvar and Vaginal Atrophy Remains Inadequate. <i>Journal of Sexual Medicine</i> , 2017, 14, 425-433.	0.3	91

#	ARTICLE	IF	CITATIONS
37	Vulvovaginal Issues in Mature Women. Mayo Clinic Proceedings, 2017, 92, 449-454.	1.4	12
38	A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy. Therapeutic Advances in Medical Oncology, 2017, 9, 269-285.	1.4	44
39	Use of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause: 1-year outcomes. Menopause, 2017, 24, 810-814.	0.8	89
40	The 2017 hormone therapy position statement of The North American Menopause Society. Menopause, 2017, 24, 728-753.	0.8	836
41	Past, Present, Future. Sexual Medicine Reviews, 2017, 5, 129-130.	1.5	1
42	Ospemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial data. Menopause, 2017, 24, 1167-1174.	0.8	20
43	Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women. Journal of Women's Health, 2017, 26, 616-623.	1.5	11
44	A vaginal estradiol softgel capsule, TX-004HR, has negligible to very low systemic absorption of estradiol: Efficacy and pharmacokinetic data review. Maturitas, 2017, 99, 51-58.	1.0	18
45	Etiology, pathophysiology and biomarkers of interstitial cystitis/painful bladder syndrome. Archives of Gynecology and Obstetrics, 2017, 295, 1341-1359.	0.8	170
46	Safety and long-term efficacy of fractional CO 2 laser treatment in women suffering from genitourinary syndrome of menopause. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 213, 39-44.	0.5	73
47	A conversation about hormone therapy: is there an appropriate dose, route, and duration of use?. Menopause, 2017, 24, 1221-1235.	0.8	9
48	Estetrol, a Fetal Selective Estrogen Receptor Modulator, Acts on the Vagina of Mice through Nuclear Estrogen Receptor $\beta$ Activation. American Journal of Pathology, 2017, 187, 2499-2507.	1.9	28
49	Long-term reliability of fractioned CO2 laser as a treatment for vulvovaginal atrophy (VVA) symptoms. Archives of Gynecology and Obstetrics, 2017, 296, 973-978.	0.8	31
50	CO 2 -laser for the genitourinary syndrome of menopause. How many laser sessions?. Maturitas, 2017, 104, 24-28.	1.0	61
51	Application of the 21-item Vulvovaginal Symptoms Questionnaire in postmenopausal Spanish women. Menopause, 2017, 24, 1295-1301.	0.8	12
52	The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. Menopause, 2017, 24, 409-416.	0.8	60
53	Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR. Menopause, 2017, 24, 894-899.	0.8	10
54	Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause. Menopause, 2017, 24, 1246-1256.	0.8	33

#	ARTICLE	IF	CITATIONS
55	Microablative fractional CO2 laser for the genitourinary syndrome of menopause: power of 30 or 40ÅW?. <i>Lasers in Medical Science</i> , 2017, 32, 1865-1872.	1.0	27
56	Shining the light on genitourinary syndrome of menopause in survivors of breast cancer. <i>Menopause</i> , 2017, 24, 1336-1337.	0.8	7
57	The menopausal woman. <i>Nurse Practitioner</i> , 2017, 42, 43-49.	0.2	2
58	Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial. <i>Menopause</i> , 2017, 24, 1003-1010.	0.8	26
59	Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis. <i>Maturitas</i> , 2017, 103, 78-88.	1.0	96
60	Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause. <i>Lasers in Surgery and Medicine</i> , 2017, 49, 160-168.	1.1	134
61	Sjögren Syndrome and Other Causes of Sicca in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2017, 33, 87-103.	1.0	34
62	Female Sexual Dysfunction—Medical and Psychological Treatments, Committee 14. <i>Journal of Sexual Medicine</i> , 2017, 14, 1463-1491.	0.3	69
64	New therapeutic option in genitourinary syndrome of menopause: pilot study using microablative fractional radiofrequency. <i>Einstein (Sao Paulo, Brazil)</i> , 2017, 15, 445-451.	0.3	28
66	An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for the assessment of sexual health of women with pelvic floor dysfunction. <i>Neurourology and Urodynamics</i> , 2018, 37, 1220-1240.	0.8	56
67	Perspectives on counseling patients about menopausal hormone therapy: strategies in a complex data environment. <i>Menopause</i> , 2018, 25, 937-949.	0.8	13
68	Improvements to the Vulva, Vestibule, Urethral Meatus, and Vagina in Women Treated With Ospemifene for Moderate to Severe Dyspareunia: A Prospective Vulvosopic Pilot Study. <i>Sexual Medicine</i> , 2018, 6, 154-161.	0.9	27
71	No. 358-Intravaginal Laser for Genitourinary Syndrome of Menopause and Stress Urinary Incontinence. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2018, 40, 503-511.	0.3	16
72	No 358-Traitement du syndrome g�nito-urinaire de la m�nopause et de l'incontinence � l'effort par laser vaginal. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2018, 40, 512-521.	0.3	1
73	Menopausal urogenital changes: welcome expansion of management options over the past 25 years. <i>Menopause</i> , 2018, 25, 471-475.	0.8	3
74	Intravaginal DHEA for the Treatment of Vulvovaginal Atrophy, <i>Intracrinology at Work. ISGE Series</i> , 2018, , 269-284.	0.2	1
75	Vulvar and vaginal fractional CO2 laser treatments for genitourinary syndrome of menopause. <i>Menopause</i> , 2018, 25, 571-573.	0.8	19
76	Symptoms of menopause — global prevalence, physiology and implications. <i>Nature Reviews Endocrinology</i> , 2018, 14, 199-215.	4.3	344

#	ARTICLE	IF	CITATIONS
77	Vulvo-vaginal rejuvenation: Fact or fiction? Fractional carbon dioxide laser for genitourinary syndrome of menopause. <i>Australasian Journal of Dermatology</i> , 2018, 59, 341-343.	0.4	4
78	Concentration range of serum sex steroids in normal postmenopausal women and those with diagnosis of vulvovaginal atrophy. <i>Menopause</i> , 2018, 25, 293-300.	0.8	6
79	Exploring knowledge, attitudes and experience of genitourinary symptoms in women with early breast cancer on adjuvant endocrine therapy. <i>European Journal of Cancer Care</i> , 2018, 27, e12820.	0.7	7
80	Towards optimization of estrogen receptor modulation in medicine. , 2018, 189, 123-129.		21
81	An international Urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for the assessment of sexual health of women with pelvic floor dysfunction. <i>International Urogynecology Journal</i> , 2018, 29, 647-666.	0.7	53
82	Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms. <i>JAMA Internal Medicine</i> , 2018, 178, 681.	2.6	133
83	The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women. <i>Mayo Clinic Proceedings</i> , 2018, 93, 467-487.	1.4	166
84	Psychometric Evaluation of the Chinese Breast Cancer Prevention Trial Symptom Scale. <i>Cancer Nursing</i> , 2018, 41, E18-E30.	0.7	1
85	Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials. <i>Journal of Women's Health</i> , 2018, 27, 14-23.	1.5	48
86	A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom. <i>Menopause</i> , 2018, 25, 133-138.	0.8	23
87	Restoring vaginal function in postmenopausal women with genitourinary syndrome of menopause. <i>Menopause</i> , 2018, 25, 106-108.	0.8	3
88	Female Urinary Incontinence. <i>Physician Assistant Clinics</i> , 2018, 3, 69-82.	0.1	1
89	The most bothersome symptom of vaginal atrophy: Evidence from the observational AGATA study. <i>Maturitas</i> , 2018, 108, 18-23.	1.0	36
90	A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom. <i>Journal of Women's Health</i> , 2018, 27, 231-237.	1.5	33
91	Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. <i>Menopause</i> , 2018, 25, 21-28.	0.8	160
92	The impact of genitourinary syndrome of menopause on well-being, functioning, and quality of life in postmenopausal women. <i>Menopause</i> , 2018, 25, 1418-1423.	0.8	29
93	High and dry: recognizing the impact of genitourinary syndrome of menopause. <i>Menopause</i> , 2018, 25, 1401-1402.	0.8	0
94	Genitourinary syndrome of menopause treatment using lasers and temperature-controlled radiofrequency. <i>Przegląd Menopauzalny</i> , 2018, 17, 185-189.	0.6	11

#	ARTICLE	IF	CITATIONS
97	In Reply:. Menopause, 2018, 25, 1167-1168.	0.8	0
98	Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause, 2018, 25, 1069-1085.	0.8	122
99	Genitourinary Changes with Aging. Obstetrics and Gynecology Clinics of North America, 2018, 45, 737-750.	0.7	35
100	The 2017 hormone therapy position statement of The North American Menopause Society. Menopause, 2018, 25, 1362-1387.	0.8	99
102	Sexual Health in Women. Journal of Women's Health, 2018, 27, 1082-1085.	1.5	1
103	BMS " Consensus statement. Post Reproductive Health, 2018, 24, 133-138.	0.3	20
104	Menopause. Primary Care - Clinics in Office Practice, 2018, 45, 625-641.	0.7	35
105	Sexual Desire in Women According to Reproductive Milestones. Current Sexual Health Reports, 2018, 10, 360-369.	0.4	2
106	Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause, 2018, 25, 1339-1353.	0.8	56
107	Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4146-4154.	1.8	42
108	More evidence why the product labeling for low-dose vaginal estrogen should be changed?. Menopause, 2018, 25, 4-6.	0.8	5
109	Genitourinary Syndrome of Menopause. Clinical Obstetrics and Gynecology, 2018, 61, 508-516.	0.6	68
110	Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. Menopause, 2018, 25, 596-608.	0.8	143
111	Update on Sjögren Syndrome and Other Causes of Sicca in Older Adults. Rheumatic Disease Clinics of North America, 2018, 44, 419-436.	0.8	45
113	Efficacy of vaginal therapies alternative to vaginal estrogens on sexual function and orgasm of menopausal women: A systematic review and meta-analysis of randomized controlled trials. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 229, 45-56.	0.5	40
114	The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. Menopause, 2018, 25, 837-847.	0.8	105
115	Not time to abandon use of local vaginal hormone therapies. Menopause, 2018, 25, 855-858.	0.8	9
116	Sexual activity and vaginal symptoms in the postintervention phase of the Women's Health Initiative Hormone Therapy Trials. Menopause, 2018, 25, 252-264.	0.8	9

#	ARTICLE	IF	CITATIONS
117	Managing common problems in the menopause. <i>InnovAiT</i> , 2018, 11, 378-386.	0.0	3
118	1.7 micron optical coherence tomography for vaginal tissue characterization in vivo. <i>Lasers in Surgery and Medicine</i> , 2019, 51, 120-126.	1.1	16
119	Vitamin E as alternative local treatment in genitourinary syndrome of menopause: a randomized controlled trial. <i>International Urogynecology Journal</i> , 2019, 30, 831-837.	0.7	15
121	Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women. <i>Frontiers in Endocrinology</i> , 2019, 10, 561.	1.5	90
122	Vaginal CO <sub>2</sub> laser for the treatment of vulvovaginal atrophy in women with breast cancer: LAAVA pilot study. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 135-140.	1.1	39
123	Current Treatment Modalities for the Genitourinary Syndrome of Menopause. , 2019, , 187-203.		0
124	Time for Action: Managing Genitourinary Syndrome of Menopause. <i>Journal of Oncology Practice</i> , 2019, 15, 371-372.	2.5	5
125	The Effect of Fractional CO <sub>2</sub> Laser Treatment on the Symptoms of Pelvic Floor Dysfunctions: Pelvic Floor Distress Inventoryâ€20 Questionnaire. <i>Lasers in Surgery and Medicine</i> , 2019, 51, 882-886.	1.1	21
127	A 56-Year-Old Woman with Dyspareunia. , 2019, , 304-306.		0
128	Practical Treatment Considerations in the Management of Genitourinary Syndrome of Menopause. <i>Drugs and Aging</i> , 2019, 36, 897-908.	1.3	60
129	Treatment of genitourinary syndrome of menopause: the potential effects of intravaginal ultralow-concentration oestriol and intravaginal dehydroepiandrosterone on quality of life and sexual function. <i>Przegląd Menopauzalny</i> , 2019, 18, 116-122.	0.6	6
130	Psychosomatic and vasomotor symptom changes during transition to menopause. <i>Przegląd Menopauzalny</i> , 2019, 18, 110-115.	0.6	22
131	Treatment of Vulvovaginal Atrophy. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1910.	3.8	6
132	Topical treatment of vaginal dryness with a non-hormonal cream in women undergoing breast cancer treatment - An open prospective multicenter study. <i>PLoS ONE</i> , 2019, 14, e0210967.	1.1	9
133	The Vulvar Vestibule, a Small Tissue with a Central Position: Anatomy, Embryology, Pain Mechanisms, and Hormonal Associations. <i>Current Sexual Health Reports</i> , 2019, 11, 60-66.	0.4	1
134	Clinician knowledge, attitudes, and barriers to management of vulvovaginal atrophy: variations in primary care and gynecology. <i>Menopause</i> , 2019, 26, 265-272.	0.8	13
135	Assessing symptomatic vulvar, vaginal, and lower urinary tract atrophy. <i>Climacteric</i> , 2019, 22, 348-351.	1.1	13
136	The Rationale for Photobiomodulation Therapy of Vaginal Tissue for Treatment of Genitourinary Syndrome of Menopause: An Analysis of Its Mechanism of Action, and Current Clinical Outcomes. <i>Photobiomodulation, Photomedicine, and Laser Surgery</i> , 2019, 37, 395-407.	0.7	10



#	ARTICLE	IF	CITATIONS
137	Menopausal Hormone Therapy. JAMA - Journal of the American Medical Association, 2019, 321, 2458.	3.8	28
138	Sexual Function in Postmenopausal Women and Serum Androgens: A Review Article. International Journal of Sexual Health, 2019, 31, 244-256.	1.2	4
139	The Potential of Hormonal Contraception to Influence Female Sexuality. International Journal of Reproductive Medicine, 2019, 2019, 1-9.	0.4	16
140	TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women. Climacteric, 2019, 22, 412-418.	1.1	7
141	Current Resources for Evidence-Based Practice, May/June, 2019. Journal of Midwifery and Women's Health, 2019, 64, 347-351.	0.7	0
142	Pharmacotherapy for the treatment of vaginal atrophy. Expert Opinion on Pharmacotherapy, 2019, 20, 821-835.	0.9	38
143	Pelvic floor dysfunction in midlife women. Climacteric, 2019, 22, 270-276.	1.1	25
144	Vulvar Cosmetics. , 2019, , 81-89.		0
145	Principles of Medical Treatment. , 2019, , 49-56.		0
146	Vulvar Erosions: Excoriations, Erosive Lichen Planus, and Fissures. , 2019, , 315-318.		0
148	Microablative fractional CO2 laser for the genitourinary syndrome of menopause: up to 12-month results. Menopause, 2019, 26, 248-255.	0.8	48
149	Female Cosmetic Genital Reconstruction: a Review of Current Trends, Treatments, and Techniques. Current Sexual Health Reports, 2019, 11, 44-51.	0.4	2
150	Dyspareunia in Women: Updates in Mechanisms and Current/Novel Therapies. Current Sexual Health Reports, 2019, 11, 9-20.	0.4	4
151	Genitourinary syndrome of menopause (GSM) and laser VEL: a review. Hormone Molecular Biology and Clinical Investigation, 2020, 41, .	0.3	8
152	Fractional CO2 laser versus promestriene and lubricant in genitourinary syndrome of menopause: a randomized clinical trial. Menopause, 2019, 26, 833-840.	0.8	62
153	Women's experience of vulvovaginal symptoms associated with menopause. Menopause, 2019, 26, 341-349.	0.8	26
154	Measurement properties of patient-reported outcome measures (PROMs) for women with genitourinary syndrome of menopause: a systematic review. Menopause, 2019, 26, 1342-1353.	0.8	19
155	Early onset of action with a 17 $\beta$ -estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia. Menopause, 2019, 26, 1259-1264.	0.8	5

#	ARTICLE	IF	CITATIONS
156	Critical analysis of methods for assessing genitourinary syndrome of menopause used in clinical trials. <i>Menopause</i> , 2019, 26, 1436-1442.	0.8	10
157	WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history. <i>Menopause</i> , 2019, 26, 124-131.	0.8	34
158	Genitourinary syndrome of menopause: in their own wordsâ€”development of a new patient-reported outcome measure. <i>Menopause</i> , 2019, 26, 335-336.	0.8	0
159	Women harmed by vaginal laser for treatment of GSMâ€”the latest casualties of fear and confusion surrounding hormone therapy. <i>Menopause</i> , 2019, 26, 338-340.	0.8	7
160	Female Sexual Dysfunction. <i>Obstetrics and Gynecology</i> , 2019, 134, e1-e18.	1.2	84
161	A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause. <i>Menopause</i> , 2019, 26, 431-453.	0.8	65
162	An individualized approach to the management of vaginal atrophy in Latin America. <i>Menopause</i> , 2019, 26, 919-928.	0.8	4
163	Female Genital and Vaginal Plastic Surgery: An Overview. <i>Plastic and Reconstructive Surgery</i> , 2019, 144, 284e-297e.	0.7	30
164	Guidelines for the Evaluation and Treatment of Perimenopausal Depression: Summary and Recommendations. <i>Journal of Women's Health</i> , 2019, 28, 117-134.	1.5	96
165	The use of laser in urogynaecology. <i>International Urogynecology Journal</i> , 2019, 30, 683-692.	0.7	27
166	IUGA committee opinion: laser-based vaginal devices for treatment of stress urinary incontinence, genitourinary syndrome of menopause, and vaginal laxity. <i>International Urogynecology Journal</i> , 2019, 30, 371-376.	0.7	64
167	The results of new low dose fractional CO <sub>2</sub> Laser â€” A prospective clinical study in France. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2020, 49, 101614.	0.6	10
168	Vulvar diseases. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1287-1298.	0.6	34
169	Genitourinary syndrome of menopause. <i>Post Reproductive Health</i> , 2020, 26, 111-114.	0.3	12
170	Ospemifene plus fractional CO <sub>2</sub> laser: a powerful strategy to treat postmenopausal vulvar pain. <i>Gynecological Endocrinology</i> , 2020, 36, 431-435.	0.7	7
171	Prevalence of depression and anxiety in women newly diagnosed with vulvovaginal atrophy and dyspareunia. <i>Menopause</i> , 2020, 27, 134-142.	0.8	14
172	The Effect of Vaginal Microablative Fractional CO <sub>2</sub> Laser Treatment on Vaginal Cytology. <i>Lasers in Surgery and Medicine</i> , 2020, 52, 708-712.	1.1	16
173	Safety of vaginal estrogens: a systematic review. <i>Menopause</i> , 2020, 27, 339-360.	0.8	35

#	ARTICLE	IF	CITATIONS
174	Vaginitis in Nonpregnant Patients. <i>Obstetrics and Gynecology</i> , 2020, 135, e1-e17.	1.2	53
175	Biocompatibility and zinc release testing of a zinc-containing vaginal gel. <i>Menopause</i> , 2020, 27, 143-149.	0.8	3
176	Exercise and Quality of Life in Women with Menopausal Symptoms: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 7049.	1.2	38
177	Vaginal laser treatment of genitourinary syndrome of menopause: does the evidence support the FDA safety communication?. <i>Menopause</i> , 2020, 27, 1177-1184.	0.8	21
179	The Fractional CO <sub>2</sub> Laser for the Treatment of Genitourinary Syndrome of Menopause: A Prospective Multicenter Cohort Study. <i>Lasers in Surgery and Medicine</i> , 2021, 53, 647-653.	1.1	12
180	Postmenopausal Hormone Therapy—Local and Systemic: A Pharmacologic Perspective. <i>Journal of Clinical Pharmacology</i> , 2020, 60, S74-S85.	1.0	9
181	Estradiol softgel inserts for the treatment of VVA symptoms: an expert opinion. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 1573-1581.	2.4	4
182	Improving the identification of genitourinary syndrome of menopause through the utilization of the Day-to-Day Impact of Vaginal Aging questionnaire. <i>Menopause</i> , 2020, 27, 1295-1301.	0.8	4
184	The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. <i>Menopause</i> , 2020, 27, 976-992.	0.8	235
185	Effects of vaginal administration of conjugated estrogens tablet on sexual function in postmenopausal women with sexual dysfunction: a double-blind, randomized, placebo-controlled trial. <i>BMC Women's Health</i> , 2020, 20, 173.	0.8	8
186	Bioidentical Oral 17 $\beta$ -Estradiol and Progesterone for the Treatment of Moderate to Severe Vasomotor Symptoms of Menopause. <i>Annals of Pharmacotherapy</i> , 2020, 55, 106002802098261.	0.9	0
187	Vaginal elasticity is significantly decreased in vaginal atrophy: a strain elastography study. <i>Menopause</i> , 2020, 27, 1420-1424.	0.8	1
188	Prevention and treatment of cystitis during menopause: efficacy of a nutraceutical containing D-mannose, inulin, cranberry, bearberry, <i>Olea europaea</i> , <i>Orthosiphon</i> and <i>Lactobacillus acidophilus</i> . <i>Przegląd Menopauzalny</i> , 2020, 19, 130-134.	0.6	13
189	Quality of Life and Menopause. , 2020, , .		2
190	Transabdominal ultrasonography: A non-invasive method for diagnosing vaginal atrophy. <i>Post Reproductive Health</i> , 2020, 26, 220-226.	0.3	3
191	Interferential current: a new option for the treatment of sexual complaints in women with premature ovarian insufficiency using systemic hormone therapy: a randomized clinical trial. <i>Menopause</i> , 2020, 27, 519-525.	0.8	2
192	Workshop on normal reference ranges for estradiol in postmenopausal women: commentary from The North American Menopause Society on low-dose vaginal estrogen therapy labeling. <i>Menopause</i> , 2020, 27, 611-613.	0.8	5
193	Effectiveness of hyaluronate-based pessaries in the treatment of vulvovaginal atrophy in postmenopausal women. <i>Climacteric</i> , 2020, 23, 519-524.	1.1	16

#	ARTICLE	IF	CITATIONS
194	Bacterial vaginosis diagnosis and treatment in postmenopausal women: a survey of clinician practices. <i>Menopause</i> , 2020, 27, 679-683.	0.8	4
195	A cost-effectiveness analysis of vaginal carbon dioxide laser therapy compared with standard medical therapies for genitourinary syndrome of menopause-associated dyspareunia. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 890.e1-890.e12.	0.7	15
196	Carbon dioxide laser treatment for vulvovaginal atrophy in women treated for breast cancer: Preliminary results of the feasibility EPIONE trial. <i>Annales De Chirurgie Plastique Et Esthetique</i> , 2020, 65, e23-e31.	0.2	60
197	Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial. <i>Menopause</i> , 2020, 27, 526-534.	0.8	25
198	Analysis of the Impact of Type 2 Diabetes on the Psychosocial Functioning and Quality of Life of Perimenopausal Women. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 4349.	1.2	3
199	Diagnosis and Management of Vulvar Skin Disorders. <i>Obstetrics and Gynecology</i> , 2020, 136, e1-e14.	1.2	25
200	Vulvo-Vaginal Atrophy (VVA). , 2020, , 105-111.		2
201	Female Sexual Dysfunction. <i>Obstetrics and Gynecology</i> , 2020, 136, 174-186.	1.2	15
202	Optical Vaginal Biopsy Using Optical Coherence Tomography. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2020, 26, 155-158.	0.6	8
203	Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement. <i>Gynecologic Oncology</i> , 2020, 157, 303-306.	0.6	30
204	Response letter to comments related to "The effect of microablative fractional CO2 laser on vaginal flora of postmenopausal women" • <i>Neurourology and Urodynamics</i> , 2020, 39, 1026-1027.	0.8	0
205	An overview of dehydroepiandrosterone (EM-760) as a treatment option for genitourinary syndrome of menopause. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 409-415.	0.9	15
206	Hormone Therapy for Postmenopausal Women. <i>New England Journal of Medicine</i> , 2020, 382, 446-455.	13.9	119
207	Sexual Health Issues in Cancer Survivors. <i>Seminars in Oncology Nursing</i> , 2020, 36, 150981.	0.7	8
208	&lt;p&gt; Ospemifene in the Management of Vulvar and Vaginal Atrophy: Focus on the Assessment of Patient Acceptability and Ease of Use&lt;p&gt;. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 55-62.	0.8	13
209	Clinical Effects of Early or Surgical Menopause. <i>Obstetrics and Gynecology</i> , 2020, 135, 853-868.	1.2	63
211	How Nurse Practitioners Approach Treatment of Genitourinary Syndrome of Menopause. <i>Journal for Nurse Practitioners</i> , 2020, 16, 136-142.	0.4	3
212	Local treatment with a polycarbophil-based cream in postmenopausal women with genitourinary syndrome of menopause. <i>International Urogynecology Journal</i> , 2021, 32, 317-322.	0.7	3

#	ARTICLE	IF	CITATIONS
213	Effective Prevention of Recurrent UTIs With Vaginal Estrogen: Pearls for a Urological Approach to Genitourinary Syndrome of Menopause. <i>Urology</i> , 2021, 151, 31-36.	0.5	8
214	Management of urinary incontinence in postmenopausal women: An EMAS clinical guide. <i>Maturitas</i> , 2021, 143, 223-230.	1.0	27
215	The Evolution of the Female Sexual Disorder/Dysfunction Definitions, Nomenclature, and Classifications: A Review of DSM, ICSM, ISSWSH, and ICD. <i>Sexual Medicine Reviews</i> , 2021, 9, 36-56.	1.5	43
216	Update: The Clinical Role of Vaginal Lasers for the Treatment of the Genitourinary Syndrome of Menopause. <i>Urology</i> , 2021, 151, 2-7.	0.5	7
217	Vaginal Er:YAG laser application in the menopausal ewe model: a randomised estrogen and sham-controlled trial. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 1087-1096.	1.1	22
218	The Menopause Transition: Signs, Symptoms, and Management Options. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1-15.	1.8	146
219	Insight on the Intracrinology of Menopause: Androgen Production within the Human Vagina. <i>Endocrinology</i> , 2021, 162, .	1.4	20
220	Characterizing nocturia among Belgian healthy postmenopausal women: Prevalence, degree of bother, etiology and risk factors for nocturia. <i>Maturitas</i> , 2021, 143, 41-46.	1.0	5
221	CO <sub>2</sub> laser and the genitourinary syndrome of menopause: a randomized sham-controlled trial. <i>Climacteric</i> , 2021, 24, 187-193.	1.1	35
223	Menopause Management. , 2021, , 1-14.		0
224	Vulvovaginal atrophy of menopause and its impact on sexual function in an Italian clinical cohort of post-menopausal women. <i>Journal of Obstetrics and Gynaecology</i> , 2021, 41, 290-297.	0.4	1
225	Nocturia through the menopausal transition and beyond: a narrative review. <i>International Urogynecology Journal</i> , 2021, 32, 1097-1106.	0.7	10
226	Pharmacologic management of nocturnal polyuria: a contemporary assessment of efficacy, safety, and progress toward individualized treatment. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722098843.	0.9	9
227	Updates on Therapeutic Alternatives for Genitourinary Syndrome of Menopause: Hormonal and Non-Hormonal Managements. <i>Journal of Menopausal Medicine</i> , 2021, 27, 1.	0.3	13
228	Bladder Outlet Obstruction and Overactive Bladder in Females. <i>Urodynamics, Neurourology and Pelvic Floor Dysfunctions</i> , 2021, , 53-65.	0.0	0
229	The short-term efficacy and safety of fractional CO <sub>2</sub> laser therapy for vulvovaginal symptoms in menopause, breast cancer, and lichen sclerosus. <i>Menopause</i> , 2021, 28, 511-516.	0.8	14
230	Postmenopausal women in gynecological care. <i>Przegląd Menopauzalny</i> , 2021, 20, 88-98.	0.6	6
231	Energy-based devices in gynecology: the new frontier for the treatment of genitourinary syndrome of postmenopause?. <i>Clinics</i> , 2021, 76, e3066.	0.6	4

#	ARTICLE	IF	CITATIONS
233	The genitourinary syndrome of menopause. <i>Menopause</i> , 2021, 28, 579-588.	0.8	42
234	Genitourinary syndrome of menopause in Chinese perimenopausal and postmenopausal women. <i>Climacteric</i> , 2021, 24, 297-304.	1.1	5
235	Clinical Guidelines for Female Lower Urinary Tract Symptoms (second edition). <i>International Journal of Urology</i> , 2021, 28, 474-492.	0.5	18
236	Genitourinary syndrome of menopause: a systematic review on prevalence and treatment. <i>Menopause</i> , 2021, 28, 706-716.	0.8	43
237	Genitourinary Symptoms in Breast Cancer Survivors: Prevalence, Correlates, and Relationship With Sexual Functioning. <i>Oncology Nursing Forum</i> , 2021, 48, 229-241.	0.5	4
238	Sustainability of vaginal estrogens for genitourinary syndrome of menopause – a systematic review. <i>Climacteric</i> , 2021, 24, 551-559.	1.1	9
239	Modern management of genitourinary syndrome of menopause. <i>Faculty Reviews</i> , 2021, 10, 25.	1.7	10
240	The therapeutic effect of dehydroepiandrosterone (DHEA) on vulvovaginal atrophy. <i>Pharmacological Research</i> , 2021, 166, 105509.	3.1	7
241	Association of Vaginal Microbiota With Signs and Symptoms of the Genitourinary Syndrome of Menopause Across Reproductive Stages. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 1542-1550.	1.7	25
242	Vestibular Mucosa Thickness Measured by Ultrasound in Patients Affected by Vestibulodynia: A Case-Control Study. <i>Sexual Medicine</i> , 2021, 9, 100320-100320.	0.9	3
243	Predictors of genitourinary syndrome in women of elderly reproductive age after hysterectomy. <i>ScienceRise: Medical Science</i> , 2021, , 10-13.	0.0	0
244	The Gynogram: A Multicentric Validation of a New Psychometric Tool to Assess Coital Pain Associated With VVA and Its Impact on Sexual Quality of Life in Menopausal Women. <i>Journal of Sexual Medicine</i> , 2021, 18, 955-965.	0.3	7
245	A Double-Blind Randomized Sham-Controlled Trial to Evaluate the Efficacy of Fractional Carbon Dioxide Laser Therapy on Genitourinary Syndrome of Menopause. <i>Journal of Sexual Medicine</i> , 2021, 18, 761-769.	0.3	28
246	Comparison of topical fractional CO2 laser and vaginal estrogen for the treatment of genitourinary syndrome in postmenopausal women: a randomized controlled trial. <i>Menopause</i> , 2021, 28, 756-763.	0.8	27
247	Evaluation of endometrial progesterone receptor expression after 12 weeks of exposure to a low-dose vaginal estradiol insert. <i>Menopause</i> , 2021, 28, 998-1003.	0.8	5
249	Genitourinary symptoms in women with breast cancer: what do oncology health professionals think and do about them?. <i>Breast Cancer</i> , 2021, 28, 1243-1251.	1.3	4
250	Influence of phytoestrogens on endometrial thickness: a systematic review and meta-analysis. <i>Climacteric</i> , 2022, 25, 118-127.	1.1	1
251	Association between premature ovarian insufficiency and gut microbiota. <i>BMC Pregnancy and Childbirth</i> , 2021, 21, 418.	0.9	23

#	ARTICLE	IF	CITATIONS
252	Assessing the Concordance Between Urogenital and Vaginal Microbiota: Can Urine Specimens Be Used as a Proxy for Vaginal Samples?. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 671413.	1.8	9
254	Vaginal collagen I and III changes after carbon dioxide laser application in postmenopausal women with the genitourinary syndrome: a pilot study. <i>Climacteric</i> , 2022, 25, 186-194.	1.1	10
255	Clinically Used Hormone Formulations Differentially Impact Memory, Anxiety-Like, and Depressive-Like Behaviors in a Rat Model of Transitional Menopause. <i>Frontiers in Behavioral Neuroscience</i> , 2021, 15, 696838.	1.0	10
256	Cardiovascular Changes in Menopause. <i>Current Cardiology Reviews</i> , 2021, 17, e230421187681.	0.6	15
257	Female sexual dysfunction = a new schematic educational and clinical tool with enhanced etiology and classification. <i>Sexologies</i> , 2021, , .	0.5	1
258	Intravaginal 6.5Åmg prasterone administration in postmenopausal women with overactive bladder syndrome: A pilot study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 263, 67-71.	0.5	8
259	Healthcare provider knowledge, attitudes, and preferences in management of genitourinary syndrome of menopause in the Mid-South. <i>Menopause</i> , 2021, Publish Ahead of Print, 1239-1246.	0.8	4
260	Vaginal CO2 laser therapy versus sham for genitourinary syndrome of menopause management: a systematic review and meta-analysis of randomized controlled trials. <i>Menopause</i> , 2021, 28, 1316-1322.	0.8	19
261	Pulsed administration for physiological estrogen replacement in mice. <i>F1000Research</i> , 2021, 10, 809.	0.8	5
262	Vaginal microbiota during the menopausal transition: the role of lactobacilli. <i>Gynecology</i> , 2021, 23, 214-221.	0.1	1
263	Validation of the German Day-to-Day Impact of Vaginal Aging (DIVA) Questionnaire in Peri- and Postmenopausal Women. <i>Sexual Medicine</i> , 2021, 9, 100382-100382.	0.9	2
264	Sexual function analysis and clitoral vascularization in postmenopausal women with genitourinary syndrome treated with ospemifene. <i>Minerva Obstetrics and Gynecology</i> , 2023, 75, .	0.5	1
265	Managing vulvar and vestibular pain in postmenopausal women: recommendations from the Spanish Menopause Society, Sociedad EspaÃ±ola de GinecologÃ­a y Obstetricia, Sociedad EspaÃ±ola de MÃ©dicos de AtenciÃ³n Primaria y FederaciÃ³n EspaÃ±ola de Sociedades de SexologÃ­a. <i>Gynecological Endocrinology</i> , 2022, 38, 263-266.	0.7	1
266	Guideline No. 422d: Menopause and Sexuality. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2021, 43, 1334-1341.e1.	0.3	3
267	Directive clinique nÃ°422dÃ¢: MÃ©nopause et sexualitÃ©. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2021, 43, 1342-1351.e1.	0.3	0
268	Directive clinique noÃ°422bÃ¢: MÃ©nopause et santÃ© gÃ©nito-urinaire. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2021, 43, 1308-1315.e1.	0.3	0
269	â€œIt just makes me feel a little less aloneâ€. <i>Menopause</i> , 2021, Publish Ahead of Print, 1374-1384.	0.8	7
270	Guideline No. 422b: Menopause and Genitourinary Health. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2021, 43, 1301-1307.e1.	0.3	12



#	ARTICLE	IF	CITATIONS
271	Menopause and care of the mature woman. , 2022, , 255-288.e9.		0
272	Ovariectomized mice and postmenopausal women exhibit analogous loss of genital epithelial integrity.. Tissue Barriers, 2021, 9, 1865760.	1.6	3
273	Screening and Management of Female Sexual Dysfunction During the Second Half of Life. , 2019, , 165-185.		2
274	Menopausal Hormone Therapy to Prevent Chronic Conditions. , 2019, , 327-348.		1
275	GSM/VVA: Advances in Understanding and Management. ISGE Series, 2018, , 261-268.	0.2	2
276	Histological and Gene Expression Analysis of the Effects of Menopause Status and Hormone Therapy on the Vaginal Introitus and Labia Majora. Journal of Clinical Medicine Research, 2019, 11, 745-759.	0.6	7
277	Isoflavones derived from Glycine max (L.) Merr. in the treatment of vaginal atrophy: A new frontier. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2017, 63, 727-728.	0.3	4
278	Fractional CO2 Laser for Treatment of Vulvovaginal Atrophy: A Short Time Follow-up. Journal of Family & Reproductive Health, 2020, 14, 68-73.	0.4	4
279	Vaginal health index score and urogenital syndrome of menopause. Gazzetta Medica Italiana Archivio Per Le Scienze Mediche, 2018, 177, .	0.0	4
280	Effect of Vitamin D Supplement on Vulvovaginal Atrophy of the Menopause. Nutrients, 2020, 12, 2876.	1.7	12
281	Is there a time limit for systemic menopausal hormone therapy?. Cleveland Clinic Journal of Medicine, 2016, 83, 605-612.	0.6	6
282	Genitourinary syndrome of menopause: Common problem, effective treatments. Cleveland Clinic Journal of Medicine, 2018, 85, 390-398.	0.6	23
283	Solid State Vaginal Laser for the Treatment of Genitourinary Syndrome of Menopause: A Preliminary Report. Open Journal of Obstetrics and Gynecology, 2018, 08, 113-121.	0.1	5
284	The Genitourinary Syndrome of Menopause: An Overview of the Recent Data. Cureus, 2020, 12, e7586.	0.2	42
285	Efecto del Triticum Vulgare intravaginal, en el tratamiento del sÃndrome genitourinario de la menopausia, en mujeres del QuindÃo, 2017-2019.. Revista Ciencias BiomÃ©dicas (cartagena), 2021, 10, 152-162.	0.0	0
287	Menopause is more than Hot Flashes: What is Missing in Homeopathic Research? A Narrative Review. Homeopathy, 2021, , .	0.5	6
288	The role of hormone therapy in urogenital health after menopause. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, 35, 101595.	2.2	9
293	Medical management of urinary incontinence in women. Cleveland Clinic Journal of Medicine, 2017, 84, 151-158.	0.6	5



#	ARTICLE	IF	CITATIONS
294	The management of women with menopausal disorders (review of clinical guidelines). Russian Journal of Human Reproduction, 2017, 23, 115.	0.1	7
295	Current Commentaries about Deep Dyspareunia and the Genito-Urinary Syndrome of Menopause. MOJ Women S Health, 2017, 5, .	0.2	0
296	Recent Advances in the Management for Genitourinary Syndrome of Menopause. Journal of SAFOMS, 2018, 6, 65-68.	0.1	0
297	Gynecologic Disorders in the Older Woman. , 2019, , 1-38.		0
298	Womenâ€™s Health. , 2019, , 403-414.		0
299	Treatment of postmenopausal vulvovaginal atrophy with estriol: a scientific update for 2014â€“2018. Obstetrics, Gynecology and Reproduction, 2019, 13, 227-238.	0.2	6
300	Long-Term Consequences of Menopause. Endocrinology, 2020, , 335-347.	0.1	0
301	Collagenotherapy for patients with genitourinary menopausal syndrome is a new opportunity in the doctorâ€™s arsenal. Russian Bulletin of Obstetrician-Gynecologist, 2020, 20, 65.	0.0	0
302	Results of open multiâ€™centre comparative randomized study of efficiency and safety of application of three therapeutic schemes of vaginal capsules Triogynol for treatment of vaginal atrophy in postmenopausal women. Medical Alphabet, 2020, 4, 38-43.	0.0	0
303	Climacteric Syndrome. Endocrinology, 2020, , 1-26.	0.1	0
304	Correction of vaginal microbiota in patients in early and late transition to menopause. Meditsinskiy Sovet, 2020, , 130-136.	0.1	0
306	Royal jelly for genitourinary syndrome of menopause: A randomized controlled trial. Gynecology and Obstetrics Clinical Medicine, 2021, 1, 211-215.	0.2	1
307	Treatment of Vulvovaginal Atrophy with Fractional CO <sub>2</sub> Laser: Evaluating Real-World Data. Photobiomodulation, Photomedicine, and Laser Surgery, 2021, 39, 716-724.	0.7	2
309	Refinement of the German Day-to-Day Impact of Vaginal Aging questionnaire in perimenopausal and postmenopausal women using item response theory and classical test theory. Menopause, 2021, 28, 292-299.	0.8	2
310	Genitourinary syndrome of menopause and age: a new algorithm for hormonal treatment?. Menopause, 2021, 28, 109-110.	0.8	6
311	Climacteric Syndrome. Endocrinology, 2020, , 309-334.	0.1	0
312	Gynecologic Disorders in the Older Woman. , 2020, , 683-719.		0
313	Long-Term Consequences of Menopause. Endocrinology, 2020, , 1-13.	0.1	4

#	ARTICLE	IF	CITATIONS
314	“As long as I have a restroom somewhere [!], I am fine”: a qualitative study on the perspectives of peri- and postmenopausal women on the impact of the urinary component of the genitourinary syndrome of menopause (GSM). <i>BMC Women's Health</i> , 2021, 21, 391.	0.8	2
315	In Reply: <i>Menopause</i> , 2020, 27, 837-840.	0.8	0
316	The Relative Burden of Menopausal and Postmenopausal Symptoms versus Other Major Conditions: A Retrospective Analysis of the Medical Expenditure Panel Survey Data. <i>American Health and Drug Benefits</i> , 2017, 10, 311-321.	0.5	8
317	Genitourinary Syndrome of Menopause: Epidemiology, Physiopathology, Clinical Manifestation and Diagnostic. <i>Frontiers in Reproductive Health</i> , 2021, 3, .	0.6	14
318	Female genitourinary treatments in aesthetics. <i>Clinics in Dermatology</i> , 2022, 40, 259-264.	0.8	3
319	Association of Vaginal Maturation Index and Vaginal pH with the Most Bothersome Symptoms of Genitourinary Syndrome of Menopause. <i>Journal of SAFOG</i> , 2021, 13, 288-291.	0.1	6
320	Efficacy of low-dose vaginal 17 $\beta$ -estradiol versus vaginal promestriene for vulvovaginal atrophy. <i>Climacteric</i> , 2021, , 1-5.	1.1	2
321	Hormonal Approach for Postmenopausal Vulvovaginal Atrophy. <i>Frontiers in Reproductive Health</i> , 2021, 3, .	0.6	0
322	Non-infectious Benign Vaginal Conditions. , 2021, , 257-265.		0
323	Recurrent Urinary Tract Infections and Asymptomatic Bacteriuria in Adults. <i>Current Bladder Dysfunction Reports</i> , 2022, 17, 1-12.	0.2	3
324	Genitourinary and Sexual Health. , 2022, , 257-282.		0
325	Využití měřicího nástroje u žen v období klimakteria. , 2021, , 136-175.		0
326	Short-term effects of an erbium/neodymium laser combination in superficial dyspareunia: a pilot study. <i>Climacteric</i> , 2022, 25, 208-211.	1.1	7
328	CO <sub>2</sub> -Laser therapy and Genitourinary Syndrome of Menopause: A Systematic Review and Meta-Analysis. <i>Journal of Sexual Medicine</i> , 2022, 19, 452-470.	0.3	31
329	The Er:YAG vaginal laser for management of women with genitourinary syndrome of menopause (GSM). <i>Lasers in Medical Science</i> , 2022, 37, 2203-2208.	1.0	5
331	Management strategies of sexual dysfunctions in Parkinson's disease. <i>International Review of Neurobiology</i> , 2022, 162, 97-116.	0.9	0
334	“Modified Schirmer Test” as an Objective Measurement for Vaginal Dryness: A Prospective Cohort Study. <i>Diagnostics</i> , 2022, 12, 574.	1.3	2
335	Management of genitourinary syndrome of menopause in breast cancer survivors: An update. <i>World Journal of Clinical Oncology</i> , 2022, 13, 71-100.	0.9	29

#	ARTICLE	IF	CITATIONS
336	Genitourinary Syndrome of Menopause and the Role of Nurse Practitioners. <i>Journal for Nurse Practitioners</i> , 2022, , .	0.4	0
338	The effects of urinary incontinence on quality of life and sexual function in women of reproductive age. <i>Gulhane Medical Journal</i> , 2022, 64, 67-72.	0.1	1
339	Vaginal Laser Therapy for Female Stress Urinary Incontinence: New Solutions for a Well-Known Issueâ€”A Concise Review. <i>Medicina (Lithuania)</i> , 2022, 58, 512.	0.8	15
340	Skin, hair and beyond: the impact of menopause. <i>Climacteric</i> , 2022, 25, 434-442.	1.1	17
342	Characteristics of the vaginal microbiome in women with premature ovarian insufficiency. <i>Journal of Ovarian Research</i> , 2021, 14, 172.	1.3	5
343	Involutive changes in the vulvovaginal area. <i>Russian Journal of Physiotherapy Balneology and Rehabilitation</i> , 2021, 20, 161-174.	0.2	0
344	Use of Moisturizers and Lubricants for Vulvovaginal Atrophy. <i>Frontiers in Reproductive Health</i> , 2021, 3, .	0.6	5
345	Do vasomotor and genitourinary symptoms of menopause vary between sedente and migrant groups? A study on the Oraon tribal populations of Eastern India. <i>American Journal of Human Biology</i> , 2021, , e23710.	0.8	1
346	Swiss consensus on the role of DHEA in the management of genitourinary syndrome of menopause. <i>Climacteric</i> , 2021, , 1-11.	1.1	3
347	Dyspareunia in Women. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1817.	3.8	2
348	â€”I thought I had fibroids, and now I donâ€™tâ€”: a mixed method study on health-related quality of life in uterine sarcoma patients. <i>Health and Quality of Life Outcomes</i> , 2022, 20, 65.	1.0	2
349	Vulvar inflammatory disorders: A review. <i>Journal of Skin and Sexually Transmitted Diseases</i> , 0, 4, 188-195.	0.0	1
350	Vaginal hormone-free moisturising cream is not inferior to an estriol cream for treating symptoms of vulvovaginal atrophy: Prospective, randomised study. <i>PLoS ONE</i> , 2022, 17, e0266633.	1.1	5
351	Genitourinary Syndrome of Menopause. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2022, 44, 319-324.	0.3	0
352	Joint Report on Terminology for Cosmetic Gynecology. <i>International Urogynecology Journal</i> , 2022, 33, 1367-1386.	0.7	4
353	Longitudinal Effects of a Combined Program of Pelvic Floor Muscle Training and Yoga on Genitourinary Symptoms in Asian Women of Older Age: A Randomized Experimental Study. <i>Geriatric Nursing</i> , 2022, 46, 27-38.	0.9	1
354	Patterns of Sexual Activity and the Development of Sexual Pain Across the Menopausal Transition. <i>Obstetrics and Gynecology</i> , 2022, 139, 1130-1140.	1.2	5
357	The role of non-hormonal methods in treatment of urogenital menopausal syndrome: modern views. <i>Reproductive Health of Woman</i> , 2021, , 17-22.	0.0	1

#	ARTICLE	IF	CITATIONS
359	Management of postmenopausal women: Collège National des Gynécologues et Obstétriciens Français (CNGOF) and Groupe d'Etude sur la Ménopause et le Vieillessement (GEMVI) Clinical Practice Guidelines. <i>Maturitas</i> , 2022, 163, 62-81.	1.0	5
360	<i>Gynecologic Issues.</i> , 2022, , 373-382.		0
361	The 2022 hormone therapy position statement of The North American Menopause Society. <i>Menopause</i> , 2022, 29, 767-794.	0.8	178
362	The effect of systemic lupus erythematosus on sexual function in women: an updated meta-analysis based on cross-sectional studies. <i>Advances in Rheumatology</i> , 2022, 62, .	0.8	3
363	Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1347-1354.	3.0	29
364	Prasterone in the treatment of mild to moderate urge incontinence: an observational study. <i>Menopause</i> , 2022, Publish Ahead of Print, .	0.8	5
365	A Randomized, Placebo-Controlled Trial Evaluating the Single and Combined Efficacy of Radiofrequency and Hybrid Fractional Laser for Nonsurgical Aesthetic Genital Procedures in Post-Menopausal Women. <i>Aesthetic Surgery Journal</i> , 2022, 42, 1445-1459.	0.9	3
366	Optical coherence tomography evaluation of vaginal epithelial thickness during <sc>CO<sub>2</sub></sc> laser treatment: A pilot study. <i>Journal of Biophotonics</i> , 2022, 15, .	1.1	5
367	The Effect of a New Vaginal Cream (A Persian Medicine Product) on Subjective Symptoms of Vulvovaginal Atrophy in Breast Cancer Survivors. <i>International Journal of Cancer Management</i> , 2022, 15, .	0.2	0
368	Hyaluronic Acid: A Valid Therapeutic Option for Early Management of Genitourinary Syndrome of Menopause in Cancer Survivors?. <i>Healthcare (Switzerland)</i> , 2022, 10, 1528.	1.0	8
369	Vulvovaginal atrophy: issues of treatment and rehabilitation: A review. <i>Gynecology</i> , 2022, 24, 240-245.	0.1	1
370	Current therapy for patients with peri- and post-menopausal vulvovaginal atrophy. (Experience of) Tj ETQq1 1 0.784314 rgBT <sub>0</sub> /Overlo	0.0	0
371	A call for health equity when addressing menopausal symptoms. <i>Menopause</i> , 2022, 29, 1235-1236.	0.8	0
372	Intravaginal dehydroepiandrosterone for genitourinary symptoms of the menopause: Is the evidence sufficient?. <i>Post Reproductive Health</i> , 2022, 28, 237-243.	0.3	3
375	Endometrial hyperplasia, estrogen therapy, and the prevention of endometrial cancer. , 2023, , 104-124.e5.		0
376	Quality of life analysis measured with the Cervantes 16 scale in treated menopausal women with genitourinary syndrome. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 1365-1374.	0.6	0
377	Effects of Flibanserin on Subdomain Scores of the Female Sexual Function Index in Women With Hypoactive Sexual Desire Disorder. <i>Sexual Medicine</i> , 2022, 10, 100570-100570.	0.9	7
378	Menopause: Questions and Answers for Improving Homeopathic Clinical Practice. <i>Homeopathy</i> , 2023, 112, 214-225.	0.5	2

#	ARTICLE	IF	CITATIONS
379	Micro-Focused Ultrasound Therapy in Patients with Urogenital Atrophy and Vaginal Laxity. <i>Journal of Clinical Medicine</i> , 2022, 11, 6980.	1.0	0
380	Bacterial Vaginosis in Postmenopausal Women. <i>Current Infectious Disease Reports</i> , 2023, 25, 7-15.	1.3	4
381	Calidad de vida en mujeres con síndrome genitourinario de la menopausia en el Quindío, Colombia. <i>Revista Colombiana De Endocrinología, Diabetes &amp; Metabolismo</i> , 2023, 10, .	0.1	0
382	Emerging Use of Vaginal Laser to Treat Genitourinary Syndrome of Menopause for Breast Cancer Survivors: A Review. <i>Medicina (Lithuania)</i> , 2023, 59, 132.	0.8	9
383	Evaluation of the efficacy of Lactobacillus-containing feminine hygiene products on vaginal microbiome and genitourinary symptoms in pre- and postmenopausal women: A pilot randomized controlled trial. <i>PLoS ONE</i> , 2022, 17, e0270242.	1.1	5
384	The Effect of Vitamin E Supplementation in Postmenopausal Women—A Systematic Review. <i>Nutrients</i> , 2023, 15, 160.	1.7	4
385	Investigation on prevalence and risk factors associated with genitourinary syndrome of menopause in middle-aged and older women in Beijing community: a cross sectional study. <i>BMC Women's Health</i> , 2022, 22, .	0.8	6
386	Pre- versus Post-Menopausal Onset of Overactive Bladder and the Response to Vaginal Estrogen Therapy: A Prospective Study. <i>Medicina (Lithuania)</i> , 2023, 59, 245.	0.8	0
387	Effectiveness of vaginal estriol with lactobacilli on urinary symptoms in postmenopausal women: a randomized-controlled trial. <i>Menopause</i> , 2023, 30, 441-446.	0.8	0
388	Epidemiological study of genitourinary syndrome of menopause in Japan (GENJA study). <i>Menopause</i> , 2023, 30, 447-453.	0.8	2
389	Labia Majora Labiaplasty with Hyaluronic Acid. , 2023, , 147-156.		0
390	Menopause Is a Natural Condition: Does It Require to Be Corrected? For Whom and for How Long?. <i>ISGE Series</i> , 2023, , 179-192.	0.2	0
391	Emergency Gynecologic Considerations in the Older Woman. <i>Emergency Medicine Clinics of North America</i> , 2023, 41, 395-404.	0.5	0
392	Superficial dyspareunia treatment with hyperstacking of erbium:yttrium-aluminum-garnet SMOOTH laser: a short-term, pilot study in breast cancer survivors. <i>Menopause</i> , 2023, 30, 174-178.	0.8	3
393	The role of estriol in the treatment of atrophy of the mucous membrane of the lower genitourinary tract in postmenopausal women. <i>Problemy Endokrinologii</i> , 2023, 68, 157-163.	0.2	1
394	Vaginal oxygen plus hyaluronic acid on genito-urinary symptoms of breast cancer survivors. <i>Climacteric</i> , 2023, 26, 129-134.	1.1	0
395	Efficacy of Polycarbophil Moisturizing Gel in Women with Genitourinary Syndrome of Menopause: A Randomized Control Trial. <i>Journal of SAFOG</i> , 2023, 14, 719-723.	0.1	1
396	Genitourinary Syndrome of Menopause. <i>Medical Clinics of North America</i> , 2023, 107, 357-369.	1.1	4

#	ARTICLE	IF	CITATIONS
397	Management of Menopausal Symptoms. JAMA - Journal of the American Medical Association, 2023, 329, 405.	3.8	27
398	Safety and effectiveness of a novel home-use therapeutic ultrasound device for the treatment of vaginal dryness in postmenopausal women: a pilot study. Menopause, 2023, 30, 383-392.	0.8	3
399	Safety and efficacy of fractional CO2 laser treatment to the vestibule: a randomized, double-blind, sham-controlled, prospective 3-site clinical study in women with vestibular pain. Journal of Sexual Medicine, 0, , .	0.3	1
400	A randomized trial on the effectiveness and safety of 5 water-based personal lubricants. Journal of Sexual Medicine, 2023, 20, 498-506.	0.3	5
401	Psychometric evaluation of the German Day-to-Day Impact of Vaginal Aging questionnaire using data from two intervention studies. Menopause, 0, Publish Ahead of Print, .	0.8	0
402	Features of the colpocytological state and biocenosis of the vagina in menopausal women with atrophic vaginitis. Reproductive Health of Woman, 2022, , 65-70.	0.0	0
403	A multicenter, randomized, placebo-controlled study to select the minimum effective dose of estetrol in postmenopausal participants (E4Relief): part 2â€”vaginal cytology, genitourinary syndrome of menopause, and health-related quality of life. Menopause, 2023, 30, 480-489.	0.8	2
404	Interaction of Metals, Menopause and COVID-19â€”A Review of the Literature. Biology, 2023, 12, 350.	1.3	1
405	Efficacy of Erbium YAG laser treatment in overactive bladder syndrome: a randomized controlled trial. Menopause, 2023, 30, 414-420.	0.8	0
406	Evidence-based review of nonantibiotic urinary tract infection prevention strategies for women: a patient-centered approach. Current Opinion in Urology, 2023, 33, 187-192.	0.9	0
407	Sexual function and quality of life in women with idiopathic premature ovarian insufficiency. Journal of Sexual Medicine, 0, , .	0.3	0
408	Effects of ospemifene on overactive bladder in postmenopausal women with vulvovaginal atrophy. Climacteric, 2023, 26, 284-288.	1.1	3
409	Development and psychometric properties of a measurement to ascertain the impact of genitourinary symptoms on health-related quality of life in menopausal women: the Cervantes-GSM questionnaire. Menopause, 2023, 30, 512-520.	0.8	1
410	Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders. Pharmacological Reviews, 2023, 75, 554-674.	7.1	14
412	Satisfaction and medication adherence in women with vulvovaginal atrophy: the CRETA. Climacteric, 2023, 26, 437-444.	1.1	3
413	Therapeutic Choices for Genitourinary Syndrome of Menopause (GSM) in Breast Cancer Survivors: A Systematic Review and Update. Pharmaceuticals, 2023, 16, 550.	1.7	3
414	Endometrial safety of low-dose vaginal estrogens. Menopause, 2023, 30, 650-658.	0.8	0
415	Laser technologies for genitourinary syndrome of menopause. Plastic Surgery and Aesthetic Medicine, 2023, , 81.	0.1	0

#	ARTICLE	IF	CITATIONS
446	Biocenosis of the vagina. Norm. Disruption. Restoration. , 2023, , .		0
447	The Systemic Effects of Ovarian Aging. , 2023, , 35-65.		0